The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response

Immunological Reviews

Volumn 194, Issue , 2003, Pages 29-38

  Iwakoshi, Neal N ^a   Lee, Ann Hwee ^a   Glimcher, Laurie H ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HAC1P; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ANTIBODY RESPONSE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CHIMERA; CYTOKINE PRODUCTION; ENDOPLASMIC RETICULUM; GENETIC TRANSCRIPTION; LYMPHOID CELL; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SIGNAL TRANSDUCTION; STRESS; SYNOVIUM;

ANIMALS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; HUMANS; LIVER DISEASES; PLASMA CELLS; PROTEIN DENATURATION; PROTEIN FOLDING; TRANSCRIPTION FACTORS;

EID: 0038675136     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00057.x     Document Type: Review

References (61)

1. Schwartz RS. Autoimmtmity and autoimmune diseases. In: Paul WE, ed. Fundamental Immunology, 3rd edn. New York: Raven Press, Ltd. 1993;1033-1097.
2. Theofilopoulos AN, Dixon FJ. Autoimmune diseases: immunopathology and etiopathogenesis. Am J Pathol 1982;108:319-365.
3. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-1054.
4. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in FcgRII-deficient mice. Nature 1996;379:346-349.
5. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998;16:421-432.
6. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995;3:21-26.
7. Liou H-C, et al. A new member of the leucine zipper class of proteins that binds to the HLA DRα promoter. Science 1990;247:1581-1584.
8. Ono SJ, Liou H-C, Davidon R, Strominger JL, Glimcher LH. Human X-box-binding protein 1 is required for the transcription of a subset of human class II major histocompatibility genes and forms a heterodimer with c-fos. Proc Natl Acad Sci USA 1991;88:4309-4312.
9. Clauss IM, Chu M, Zhao J-L, Glimcher LH. The basic domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE-like sequences containing an ACGT core. Nucl Acids Res 1996;24:1855-1864.
10. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol 1998;63:139-152.
11. Schall TJ, Bacon K, Camp KDR, Kasparai JW, Goeddel DV. Human macrophage inflammatory protein α (MIP-1α) and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 1993;177:1821-1825.
12. Ivashkiv LB, Liou H-C, Kara CJ, Lamph WW, Verma IM, Glimcher LH. mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol 1990;10:1609-1621.
13. Yoshimura T, Fujisawa J, Yoshida M. Multiple cDNA clones encoding nuclear proteins that bind to the tax-dependent enhancer of HTLV-1: all contain a leucine zipper structure and basic amino acid domain. EMBO J 1990;9:2537-2542.
14. Clauss IM, Gravallese EM, Darling JM, Shapiro F, Glimcher MJ, Glimcher LH. In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis. Dev Dyn 1993;197:146-156.
15. Matsuzaki Y, Fujisawa J, Yoshida M. Identification of transcriptional activation domain of TREB5, a C REB/ATF family protein that binds to HTLV-1 enhancer. J Biochem (Tokyo) 1995;117:303-308.
16. Reimold AM, et al. Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med 1996;183:393-401.
17. Barberis A, Widenhorn K, Vitelli L, Busslinger M. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev 1990;4:849-859.
18. Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 2001;20:65-82.
19. Kim HJ, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 1999;162:3053-3062.
20. Chen J, Lansford R, Stewart V, Young F, Alt FW. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci USA 1993;90:4528-4532.
21. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989;1:27-35.
22. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994;77:297-306.
23. Lin Y, Wong K-K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997;276:596-599.
24. Shaffer AL, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62.
25. Soro PG, et al. Differential involvement of the transcription factor blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells. J Immunol 1999;163:611-617.
26. Morrison AM, Nutt SL, Thevenin C, Tolink A, Busslinger M. Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Sem Immunol 1998;10:133-142.
27. Usui T, et al. Overexpression of B cell-specific activator protein (BSAP/Pax-5) in a late B cell is sufficient to suppress differentiation to an Ig high producer cell with plasma cell phenotype. J Immunol 1997;158:3197-3204.
28. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001;2:1103-1108.
29. Mittrucker HW, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 1997;275:540-543.
30. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997;176:589-592.
31. Barton K, et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998;9:555-563.
32. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 2001;14:13-20.
33. Patil C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr Opin Cell Biol 2001;13:349-355.
34. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 1988;332:462-464.
35. Ruegsegger U, Leber JH, Walter P. Block of HAC1 mRNA translation by long-range base pairing is released by cytoplasmic splicing upon induction of the unfolded protein response. Cell 2001;107:103-114.
36. Shen X, et al. Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell 2001;107:893-903.
37. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001;107:881-891.
38. Calfon M, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 2002;415:92-96.
39. Cox JS, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1993;73:1197-1206.
40. Cox JS, Walter P. A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response. Cell 1996;87:391-404.
41. Tirasophon W, Welihinda AA, Kaufman RJ. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev 1998;12:1812-1824.
42. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999;397:271-274.
43. Lee K, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev 2002;16:452-466.
44. Ma Y, Hendershot LM. The unfolding tale of the unfolded protein response. Cell 2001;107:827-830.
45. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-738.
46. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect the transcription factor XBP-1. Nat Immunol 2003.
47. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
48. Hirano T, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-1801.
49. Yoshizaki K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-1367.
50. Miyasaka N, et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol 1989;52:238-247.
51. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995;34:321-325.
52. Horii Y, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989;143:3949-3955.
53. Samoilova EB, Horton JL, Hilliard B, Liu TST, Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998;161:6480-6486.
54. Kopf M, Le Gros G, Coyle AJ, Kosco-Vilbois M, Brombacher F. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol Rev 1995;148:45-69.
55. Kovalchuk AL, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002;99:1509-1514.
56. Wen XY, et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol 1999;15:173-178.
57. Akira S, Kishimoto T. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol 1997;65:1-46.
58. Kopf M, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-342.
59. Cressman DE, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-1383.
60. Thompson JS, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-2111.
61. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-307.